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ABSTRACT  
Rheumatoid Arthritis: A Literature Review and Comprehensive Treatment Analysis 
Charlie Mechling 
Director: Jonelle Hook, PTA MA 
 
Rheumatoid arthritis (RA) is a systemic and debilitating autoimmune disease. The 
varying levels of severity of rheumatoid arthritis make it notably unique. Rheumatoid 
arthritis is not strictly an inflammatory disease of the joints; it is an extensive disease 
with many extra-articular manifestations that complicate its treatment and management. 
In addition to being a disease that is internally driven by the body’s immune system, 
current research reveals the pervasive influence of environmental factors on the disease’s 
severity and activity. This literature review examines the pathophysiology of RA, its 
implications on the body, and current treatment options to ameliorate some of its 
symptoms and complications. A particular focus on the efficacy and potential value of 
diet, psychosocial interventions, physical activity, and therapeutic modalities is central to 
the current work. Evidence using a literature review of peer-reviewed articles discussing 
RA and its many facets is utilized. A survey of patients with RA reveals patient attitudes 
and discretions towards their arduous personal experiences with rheumatoid arthritis. 
Overall, the findings indicate that having a well-versed interprofessional team of 
physicians and health professionals supporting patients with rheumatoid arthritis using an 
integrated model of care, is critical to improved overall well-being and disease outcomes.  
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 iv  
 
TABLE OF CONTENTS 
CHAPTER 1: INTRODUCTION ........................................................................................ 1 
CHAPTER 2: PATHOGENESIS AND PATHOPHYSIOLOGY ....................................... 3 
CHAPTER 3: A SYSTEMIC DISEASE ............................................................................. 6 
CHAPTER 4: ARTICULAR MANIFESTATIONS ........................................................... 8 
CHAPTER 5: EXTRA-ARTICULAR MANIFESTATIONS ........................................... 10 
CHAPTER 6: ENVIRONMENTAL AND GENETIC RISK FACTORS ........................ 13 
CHAPTER 7: PHARMACOLOGICAL THERAPY ........................................................ 15 
CHAPTER 8: NON-PHARMACOLOGICAL THERAPY .............................................. 18 
CHAPTER 9: RATIONALE  ............................................................................................ 24 
CHAPTER 10: METHODS  .............................................................................................. 26 
CHAPTER 11: PATIENT SURVEY RESULTS  ............................................................. 28 
CHAPTER 12: DISCUSSION .......................................................................................... 38 
CHAPTER 13: CONCLUSION ........................................................................................ 46 
APPENDICES ................................................................................................................... 48 
 APPENDIX A: ORIGINAL IRB APPROVAL ............................................................ 49 
 APPENDIX B: FINAL IRB AMENDMENT ............................................................... 50 
 APPENDIX C: STUDENT SURVEY INFORMED CONSENT STATEMENT ........ 51 
 APPENDIX D: STUDENT SURVEY .......................................................................... 53 
REFERENCES .................................................................................................................. 55 
 
 
 
 1 
CHAPTER ONE 
Introduction 
 
 Rheumatoid Arthritis (RA) is a common chronic inflammatory autoimmune 
disease affecting over 1.5 million people in the United States, the majority of which are 
females (Gibofsky, 2012). An immune response characterized by lymphocytes, 
neutrophils, mast cells, synovial tissue cells, and platelet microparticles play a 
fundamental role in the inflammatory process within the synovial fluid (Boilard et al., 
2010) leading to synovitis, joint deformity, and structural bone damage. This 
inflammation can cause considerable levels of pain and swelling to the joints with 
ensuing severe joint dysfunction. One of the most noteworthy symptoms of RA is the 
presence of severe fatigue – which is far more intense and distinct than general fatigue 
experienced by those without an RA diagnosis. Factors associated with heightened 
fatigue levels among RA patients include medical-related issues, along with psychosocial 
and lifestyle factors. These determinants include reduced social participation, lack of 
sleep, decreased physical activity that is vital to overall well-being, and a sense of loss of 
control over the prognosis (Nikolaus et al., 2010).  
 In addition, the economic burden of RA is extensive. The total medical costs 
exceed $19 billion annually with many patients spending up to $30,000 a year on 
medications alone (Freeman, 2018). The cost in medication ranges between 8 to 24% and 
hospitalization constitutes anywhere between 17 and 88% of the total cost. Also, patients 
report a median duration of up to 39 missed workdays annually (Burton et al., 2005). 
Although research has helped formulate a better understanding of the condition, the 
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underlying pathophysiology is still not fully understood. It is suggested that epigenetic 
factors can ameliorate the interaction of genetic and environmental factors that contribute 
to the complexity and lifelong complications of this disease. The severe extra-articular 
manifestations and economic burden of this disease illustrate that it is imperative to use a 
holistic approach. Incorporating various aspects of lifestyle modifications can ensure 
better management of RA and its many manifestations.  
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CHAPTER TWO 
Pathogenesis and Pathophysiology  
 
The pathogenesis and pathophysiology of RA are not well-defined. A 
combination of biological markers and environmental factors complicate the 
understanding of RA and its systemic effect on the body. In adults, RA is typically 
classified into one of two types: seropositive rheumatoid arthritis or seronegative 
rheumatoid arthritis. Blood tests identifying the presence of rheumatoid factor (RF) and 
antibodies to citrullinated protein antigens (ACPAs) indicate seropositive RA (Nordberg 
et al., 2016). Antibodies to citrullinated proteins are pathogenic autoantibodies produced 
by B memory cells in the body’s humoral adaptive immune system. The adaptive 
immune system is characterized by lymphocytes, T and B cells, and dendritic cells that 
target pathogens in the body. Antibodies to citrullinated proteins are highly specific for 
RA because they attack extracellular citrullinated protein antigens that are produced in 
response to inflammation in body tissues and organs (Derksen et al., 2017; Surmont & 
Diamond, 2015). Recent studies suggest that the presence of these autoantibodies may 
inadvertently amplify inflammation, directly enhancing arthritis in the body (Elkon & 
Casali, 2015). Various sources indicate that these autoantibodies may be present years 
before the onset of RA-related symptoms occur, signifying the potential for systemic 
effects of RA that cannot be determined by clinical phenotypes (Brennan & Mcinnes, 
2008; Suurmond & Diamond, 2015). 
In contrast to seropositive RA, seronegative RA patients are ACPA negative. In 
2010, the American College of Rheumatology redefined the classification criteria for 
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seronegative patients. The criteria deemed that seronegative patients must show 
inflammation in 10 or more joints to meet the criteria for an RA diagnosis. Joint 
inflammation occurs when the immune system attacks and thickens the synovium lining 
around the joints. If inflammation around the joints persists, the cartilage and bone within 
the joint can be permanently damaged.  
 Historically, seropositive RA has been considered to be more severe than 
seronegative RA, but recent findings propose otherwise. A 2016 report in the Annals of 
the Rheumatic Diseases found that in a study of 234 patients with either a seropositive or 
seronegative RA diagnosis, the seronegative patients reported higher disease activity in 
comparison to the seropositive patients (Nordberg et al., 2016). This insight could be of 
interest to diagnosing physicians and rheumatologists as swollen joints and the presence 
of ACPA may not be the most useful factors in identifying the severity of disease. Further 
research should be enacted to determine the varying severity levels of seropositive versus 
seronegative RA and their criteria for diagnosis.  
The second component that adds to the complexity of the development and 
progression of RA is the interaction between the body’s immune response to 
environmental factors. Smoking, infectious agents, periodontal disease, the 
gastrointestinal microbiome, and adverse life events are all related to the onset of 
rheumatoid arthritis (McInnes & Schett, 2011). Reports indicate that smoking, one of the 
strongest known risk factors for RA, may perpetuate the production of citrullinated 
proteins, resulting in the subsequent development of ACPAs (Demoruelle & Deane, 
2011). The interaction between what the body experiences externally and how it reacts 
internally increases the variance in predictors for disease activity and complicates the 
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understanding of the pathogenesis of RA. As new research and information regarding the 
biological and environmental factors that impact the disease become available, a better 
understanding and appreciation for the chronic, and sometimes invisible, effects of RA 
are likely to result. 
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CHAPTER THREE 
A Systemic Disease 
 
 Rheumatoid arthritis is predominantly classified by its manifestations and 
physical phenotypes in the major joints of the body. When people think of “arthritis,” 
they think of bone atrophy, aging, inflammation, and fatigue. While each of these factors 
play a role in the course of this chronic autoimmune disease, new research indicates that 
the underlying systemic involvement of RA is much greater than previously thought. 
According to Prete et al. (2011, p.124), “The natural history of the disease in most 
patients involves chronic low-grade inflammation, with periodic flares, that may 
progressively lead to joint destruction, deformity, disability and even premature death.” 
Yet, the overall effects of the disease appear to be much more intense than the symptoms 
that result from low-grade flares of inflammation.  
 Fatigue, for example, was at one time considered to be a primary symptom related 
to elevated levels of inflammation in the body. More recently, researchers believe fatigue 
to be associated with other RA-related symptoms, including depression, anxiety, and the 
inability to exercise (Moreland & Curtis, 2009). These psychosocial factors influencing 
disease activity suggest the personal burdens associated with an RA diagnosis are more 
far-reaching than presumed by early research. 
 Other indicators such as the presence of rheumatoid nodules and constitutional 
symptoms including fevers, highlight the misunderstanding of RA as being regarded as a 
type of arthritis, rather than a systemic disease. Kelly O’Neil Young, author of the book, 
Rheumatoid Arthritis Unmasked: 10 dangers of Rheumatoid Disease, provides a great 
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amount of research regarding the symptoms of RA that go beyond joint inflammation. 
She highlights how the Mayo Clinic lists fever as one of the primary symptoms of 
rheumatoid arthritis (Rheumatoid arthritis, 2019), and yet most patients who visit their 
primary care physicians or rheumatologists rarely, if ever, have their temperatures taken 
upon arrival (Young, 2017). A low-grade fever may indicate RA activity and subsequent 
flare-ups, even if there are no signs of physical inflammation or swollen joints. Similarly, 
rheumatoid nodules are a symptom of RA that “can form before joint involvement and 
may be associated with an increased risk of other extra-articular manifestations” (Prete et 
al., 2011, p.126). These nodules are subcutaneous and occur in roughly 30% of RA 
patients (Prete et al., 2011, p.126). Because rheumatoid nodules can develop before joint 
involvement, clinicians may not be aware of disease activity if a more thorough 
examination of the patient’s symptoms is not completed. 
 Current research suggests that the extent of disease activity in RA patients may be 
much more difficult to determine than once thought. This is critical for clinicians and 
researchers to consider as they move forward in determining the future of RA treatment 
and the clinical evaluation of the disease. Patients may be suffering from the systemic 
symptoms of RA without showing any signs of inflammation in the joints. This likely 
means that numerous patients could be misdiagnosed or receive treatment for RA 
considerably later than what is recommended by physician-researchers. Like most other 
chronic diseases, the early treatment and diagnosis of RA is crucial in preventing 
significant progressions and retarding the long-term severity of disease (Heidari, 2011). 
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CHAPTER FOUR 
Articular Manifestations  
 
Articular (pertaining to a joint or joints) inflammation and destruction due to RA 
is generally considered to be the primary symptom indicating disease activity. The 
destruction of the joints can lead to functional decline and increase the risk of 
comorbidity in various systems in the body (Brennan & Mcinnes, 2008). Clinicians look 
for symmetrical inflammation of the small joints in the hands and feet during an initial 
evaluation of patient symptoms (Weissman et al., 2018). Synovial inflammation can 
become so severe that the patient experiences a drastic decrease in muscle mass, referred 
to as rheumatoid cachexia. Studies suggest that rheumatoid cachexia is directly related to 
the presence of pro-inflammatory cytokines in the joints of patients with RA (Santo et al., 
2018).  
Cytokines are proteins released by cells that interact with other cells. Cytokines 
can be either anti-inflammatory or pro-inflammatory, with evidence supporting that 
specific pro-inflammatory cytokines are directly involved with pathogenic pain (Zhang & 
An, 2007). The elevated presence of cytokines in inflamed joints serve as helpful 
biomarkers for therapies directed towards mitigating the progressive destruction of the 
joints and extreme muscle loss seen in patients with rheumatoid cachexia. Understanding 
the influence of cytokines on the primary articular manifestations of RA is paramount 
towards formulating therapies that both attack pro-inflammatory cytokines to prevent 
destruction, and also to limit pathogenic pain (Zhang & An, 2007). Reducing patient pain 
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and fatigue is key to hindering the magnitude of co-morbidities and extra-articular 
manifestations that tend to develop throughout the disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 10 
CHAPTER FIVE 
Extra-Articular Manifestations 
 
 Extra-articular manifestations are the associated symptoms and conditions of RA 
that are not related to the articular joints or musculoskeletal system of the body (Cojocaru 
et al., 2010). While these are considered secondary symptoms to the articular 
manifestations in the synovial linings, they are not to be confused with complications. 
Approximately 40% of RA patients present extra-articular symptoms, with the onset 
occurring at any stage in the disease and with the likelihood of occurrence equal amongst 
both men and women (Cojocaru et al., 2010; Weissman et al., 2018). The extra-articular 
manifestations in RA patients most commonly and severely impact the heart, lungs, 
larynx, and vascular systems. Involvement with extra-articular organs positively 
correlates with the severity of the disease, contributes to increased mortality, and is 
influenced by genetic and environmental factors. (Cojocaru et al., 2010; Prete et al., 
2011). The extra-articular involvement within the major organs of the body make these 
secondary symptoms of RA dangerous and yet are often overlooked. A discussion 
regarding the severity of the complications associated with extra-articular manifestations 
will be reviewed, along with an explanation of how environmental and genetic risk 
factors complicate symptoms. 
 Rheumatoid arthritis patients often present with phonatory (of speech and sound) 
and respiratory symptoms that can be subtle and misleading, resulting in seldomly made 
diagnoses and treatment plans. Inflammation of the cricoarytenoid joint in the larynx can 
produce symptoms such as loss of voice, hoarseness, pain in the throat, vocal cord 
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dysfunction, immobility, and fixation (Young, 2017). Recent studies show that laryngeal 
involvement is seen in up to 90% of RA cases, with up to 50% of patients reporting that 
laryngeal inflammation is the sole manifestation of their RA symptoms (Hamdan & 
Sarieddine, 2013). While most laryngeal symptoms are not life-threatening, they can 
impact and restrict one’s quality of life. Aphonia, the loss of the ability to speak, results 
from inflammation in both vocal cords (Hamdan & Sarieddine, 2013). Rheumatoid 
arthritis patients who experience this type of disruption to their vocal cords must visit a 
clinician for treatment of the symptoms. In addition, patients who present with laryngeal 
symptoms and no articular symptoms may be in the early stages of RA, and the early 
detection of inflammation in the vocal cords could lead to a better disease prognosis 
(Young, 2017). However, a few clinical autopsies have found that rheumatoid 
cricoarytenoid arthritis is not always clinically detectable (Young, 2017). This can lead to 
a lack of awareness of laryngeal involvement and a subsequent delay in therapy. 
 As with laryngeal involvement, pulmonary RA manifestations can generate a 
wide spectrum of symptoms and disorders. The most common pulmonary manifestations 
are interstitial lung disease, rheumatoid nodules, and pleural effusions (Gauhar et al., 
2007), with 50% of patient cases reporting pleural involvement and only 10% being 
clinically detected (Cojocaru et al., 2010). Researchers are beginning to explore the role 
of inflammatory cytokines (the proteins found in the inflamed synovia of RA patients) to 
determine their involvement in pulmonary inflammation. While the exact effect of 
cytokines in pulmonary inflammation is not well-understood, further investigations are 
suggested to explore the role of cytokines in pulmonary involvement to formulate target 
therapies (Moreland & Curtis, 2009). Likewise, in her book, Young describes how most 
 12 
studies have shown that there is no correlation between the degree of severity of articular 
destruction and the extent of pulmonary involvement (Young, 2017). Thus, pulmonary 
symptoms could be severe, while the clinical assessment of joint, cartilage, and bone 
damage could potentially be mild. Without considering pulmonary involvement as an 
indicator of rheumatoid activity, the clinical phenotypic observation of the joints would 
fail to provide an accurate assessment of disease activity and severity. 
 In like manner to the heightened risk of developing pulmonary symptoms, the risk 
of developing coronary artery disease and heart failure is twice as likely for patients with 
RA and can be evident before an official RA diagnosis (Crowson et al., 2013, p. 622). 
Recent literature highlights the critical role of inflammation of the vasculature and its 
correlation with an increased risk of cardiovascular disease and mortality. Vascular 
leakage and atherosclerosis are examples of two vascular diseases that result from 
inflammation and a buildup of fatty material on the arterial walls. Both these diseases are 
associated with RA and contribute to high cardiovascular risk. The inflammatory proteins 
that cause synovitis, inflammation of the synovial linings of the joints, also attributes to 
vasodilation of the blood vessels and a decrease in overall blood pressure (Szekanecz & 
Koch, 2008). 
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CHAPTER SIX 
Genetic and Environmental Factors 
 
 While extra-articular manifestations can exist on their own or in conjunction with 
another, genetic predispositions and environmental risk factors can exacerbate the 
likelihood of developing RA, extra-articular manifestations, and increase mortality risk. 
Recent research coins a term ‘Preclinical RA,’ where circulating levels of RF and ACPAs 
are elevated in the bloodstream (Deane et al., 2017). This influx of autoimmunity defense 
mechanisms can be present in the body long before the clinically apparent synovitis in the 
joints. Because the propagation of autoimmunity may be present before an inflammatory-
based RA diagnosis, the genetic and environmental risk factors associated with RA may 
also be influencing the body and its systems far in advance of the swelling of the distal 
joints. Among seropositive patients, the familial genome may contribute to 50% of the 
risk of RA development (Deane et al., 2017). Within the overall genetic risk, new 
findings show that a specific group of alleles called the ‘shared epitope’ may contribute 
to 40% of the familial genome risk (Deane et al., 2017). The presence of these alleles is 
highly associated with ACPA seropositive patients and are considered to be high-risk 
alleles within the human genome. Additionally, environmental risk factors also influence 
the rate of disease and its severity. While researchers don’t know exactly when these 
environmental risk factors act in the natural history of RA, it is widely known that they 
do have an effect on the disease over time. 
Most notably, exposure to smoking and specifically to tobacco may account for 
up to 30% of environmental risk in RA patients (Deane et al., 2017). The effect of 
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smoking on the pulmonary system may attribute to high inflammation of the pleural 
cavity with patients who experience symptoms from extra-articular manifestations in the 
lungs. Further evidence also indicates that diet, the health of the microbiome, and 
exposure to silica dust, are primary environmental risk factors for the development and 
severity of RA (Badsha, 2018; Deane et al., 2017; Guahar et al., 2007). 
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CHAPTER SEVEN 
Pharmacological Therapy 
 
 Because the coordination of clinician involvement may be difficult to obtain for 
RA patients who are suffering from symptoms of extra-articular manifestations, the 
management and treatment of RA is overwhelmingly complex. Like many other chronic 
diseases, rapid pharmaceutical intervention is most beneficial within the first 12 months 
of the diagnosis. It has been established that many RA patients suffer from extra-articular 
manifestations, which also require rapid and often long-term treatment. Over time, the 
medications required of an RA patient can be difficult on the body. The most common 
medications used to treat the underlying disease and symptoms of rheumatoid arthritis are 
DMARDS (disease-modifying anti-rheumatic drugs), corticosteroids, and NSAIDS (non-
steroidal anti-inflammatory drugs) (Mota et al., 2013). 
 Disease-modifying anti-rheumatic drugs are immunosuppressive and 
immunoregulatory drugs that are designed to slow the underlying progression of RA, not 
just treat the symptoms (“DMARDS,” n.d.). Methotrexate is the most commonly 
prescribed DMARD and is generally considered to be the first line of defense in treating 
RA due to its well-established efficacy (Mota et al., 2013). While concerns surrounding 
the use of methotrexate are focused on its long-term gastrointestinal effects, numerous 
studies have found that methotrexate may also reduce cardiovascular activity in RA 
patients (Crowson et al., 2013; Salliot & Heijde, 2008), adding to its benefits as a 
disease-modifying agent. In 2013, the Brazilian Society of Rheumatology released a 
report outlining the guidelines for the drug treatment of RA, with a specific focus on the 
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use and safety of DMARDS. In their report, the authors state, “Early administration of 
DMARD treatment (less than nine months from symptom onset) produced a 33% relative 
reduction in the radiographic disease progression during the following three years” (Mota 
et al., 2013, p.162). Due to their disease-modifying abilities combined with their 
relatively safe effects on the body’s systems, DMARDS are the current standard for drug 
treatment against RA. When combined with other symptom-suppressing medication, 
DMARDS prove to be overtly suitable for treating RA.  
 Corticosteroids are a class of steroid-based drugs that target inflammation and 
pain. Their role in the body is focused on improving RA symptoms, rather than treating 
the underlying mechanisms of disease. While DMARDS can eventually treat symptoms if 
they are able to slow disease progression, symptom relief is not immediate. 
Corticosteroids target symptoms directly, resulting in fast relief. Prednisone is a well-
known corticosteroid that is commonly prescribed for RA patients. While effective at 
treating symptoms, prednisone has many side effects that contradict long-term usage 
(“Prednisone,” n.d.). Patients who are prescribed high doses of prednisone are at twice 
the risk of developing cardiovascular disease than those who are not prescribed a steroid-
based anti-inflammatory (Crowson et al., 2013, p. 624). Unless the progression of RA is 
static and under control, prednisone and other corticosteroids are not typically prescribed 
alone. Medical research suggests that the pharmacological treatment of RA is most 
successful when low doses of prednisone are used in combination with DMARDS or 
other disease-modifying medications to combat both the disease itself and its symptoms 
(Mota et al., 2013). 
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 Non-steroidal anti-inflammatory drugs are anti-inflammatory medications that 
like corticosteroids, decrease inflammation and pain. Non-steroidal anti-inflammatory 
drugs, however, are unique because they do not contain steroids. While they are 
considered to be safer for long-term use, they are not as effective at managing symptoms. 
Common NSAIDS that are used to treat RA symptoms are Aspirin, Ibuprofen, and 
Meloxicam (Freeman, 2018). Even though the strength of NSAIDS is far less comparable 
to that of corticosteroids, physicians consider renal, hepatic, and cardiovascular adverse 
long-term effects when prescribing NSAIDS to patients. Depending on the severity and 
progression of disease, some RA patients may respond well to only taking an NSAID, 
though prescribed NSAIDS are of much greater strength than over-the-counter anti-
inflammatory drugs. If the patient responds well to NSAIDS and does not have 
worsening symptoms, research suggests that in combination with DMARDS, the use of 
NSAIDS is a favorable pharmaceutical treatment plan (Mota et al., 2013). 
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CHAPTER EIGHT 
Non-pharmacological Therapy 
 
 Despite recent advances in the pharmacology realm of rheumatoid arthritis 
treatment, a comprehensive approach including non-pharmacological treatment plans and 
an interprofessional team of physicians should be the accepted protocol towards treating 
RA and its extra-articular manifestations. Even when medicine-based treatment plans are 
effective at abating disease progression or decreasing pain, a patient’s quality of life may 
still be severely impacted. Lifestyle changes, exercise, therapeutic modifications, 
psychosocial interventions, patient education, and alternative medicines are just a few 
examples of non-pharmacological treatment options that are becoming increasingly 
popular in treating RA. Empirically-supported research strongly suggests exercise, 
psychosocial treatment, and patient education/self-management systems to be distinctly 
significant in improving patient outcomes and enhancing quality of life (Cunningham & 
Kashikar-Zuck, 2013; Vlieland, 2007). Patients tend to recognize the importance of 
taking strong medications to fight the progression and symptoms of RA. At the same 
time, however, patients also often wish that they could mitigate their usage of these harsh 
pharmacology treatments to abate their strong side effects. In 2004, a group of 
investigators published a study with 29 patients who had either begun taking a DMARD 
for the first time or switched to an alternative DMARD. These patients were asked to 
voice their opinions and beliefs regarding their medication and what implications it had 
on their quality of lives. The investigators concluded that while DMARDS were believed 
to be central to many of the patients’ treatment plans, patients voiced concerns regarding 
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the long-term effects and potential ‘toxicity’ of their medications (Goodacre, 2004). 
These complex beliefs regarding the feasibility and longevity of pharmacology treatment 
may be of interest to researchers, physicians, rheumatologists, and scholars who are 
looking to evolve the medical approach to RA treatment. At this point, obtaining a 
multifaceted proposal to RA treatment is beginning to gain ground amongst 
professionals. A more in-depth discussion of possible non-pharmacological treatment 
options is described below. 
 
Diet  
 Many patients with RA explore diets and other integrative modalities as a way to 
control the disease process. Although the connection between RA and diet is still poorly 
understood, it is estimated that about half of RA patients will try dietary modifications at 
some point following their diagnosis (Badsha, 2018, p. 19). This is a logical next step as 
scientific findings have shown a compelling link between the gut microbiome and its 
influence on the immune system. Specifically, the filamentous bacteria in the gut tend to 
drive the inflammatory process through its effect on helper T cells which then activate B 
antibodies, resulting in the synovial inflammatory response (Badsha, 2018). Dietary 
changes can either exacerbate or improve disease activity via their impact on the human 
intestinal microbiome. For example, Lectin, a legume protein, has proven to influence the 
pro-inflammatory response; while Genistein, a hormonal compound also present in 
legumes, has been shown to inhibit pro-inflammatory cytokines (Badsha, 2018). Current 
research most notably reports the positive influence of polyphenols, n-3 polyunsaturated 
fatty acids (n-3 PUFAs), and monounsaturated fatty acids in RA activity suppression. A 
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2018 study by Skoczyńska & Świerkot found that RA patients consuming foods such as 
fatty fish, which contain high amounts of n-3 PUFAs, saw a significant decrease in 
disease activity. Therapeutic fasting, another modality, could help improve the pain and 
stiffness commonly seen in RA by improving gastrointestinal tract permeability and 
modulating the inflammatory process (Hafström et al., 1988; Nair, & Khawale, 2016; 
Sköldstam et al., 1979). While additional research should be conducted to better 
understand the role of diet in RA disease activity, the results of current findings are 
promising indicators of successful outcomes from dietary modification. 
 
Physical Activity 
 The importance of maintaining a regular physical activity regimen for patients 
with RA is critical towards sustaining overall well-being and cardiovascular health 
(Cooney et al., 2011; Metsios et al., 2007). A 2015 study by Salmon and colleagues 
examined the views of seven physiotherapists and two occupational therapists regarding 
physical activity and its effect on RA disease progression. Researchers agree that 
physical activity not only has a positive effect on mitigating fatigue in RA patients, but it 
also helps improve patients’ psychosocial and overall well-being (Salmon et al., 2015). 
However, it is noted that patients tend to exhibit limited physical activity due to several 
factors. Some of these factors include negative patient perceptions regarding the effect of 
exercise, lack of strength, persistent fatigue, and limited functioning (Cooney et al., 
2011). Physically inactive patients increase their risk of developing cardiovascular 
disease and/or rheumatoid cachexia. Several research studies provide substantial evidence 
that a combination of aerobic and strength training can drastically reduce disease activity 
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as well as provide additional benefits to the patient by improving functional ability and 
reducing complications. Improvement in cardiovascular, musculoskeletal, and joint 
health - as well as a reduction in pain and morning stiffness has been noted (Cooney et 
al., 2011). Engaging in high-intensity resistance training is a safe and effective way for 
patients to reverse muscular atrophy and restore strength. Additionally, aerobic exercise 
such as walking, cycling, and swimming can improve cardiovascular fitness and address 
symptoms of pain and fatigue (Cooney et al., 2011) 
 
Therapeutic Modalities  
 Therapeutic approaches, such as occupational therapy and physiotherapy, are 
essential parts of any RA treatment plan. The lack of autonomy associated with a reduced 
ability to execute activities of daily living can have a profound impact on a patient’s 
emotional and psychological state. To address this issue, a 2015 report emphasized four 
critical areas for occupational therapists (OTs) to focus on during their evaluations of 
patient priorities: patient guidance and education, joint protection and energy 
conservation, modifying activity and work environments, and implementing the use of 
assistive technologies (De Almeida et al., 2015). Occupational therapists play an integral 
role within the multidisciplinary team to aid patients as they integrate daily approaches 
that minimize difficulties in performing daily tasks. Additionally, physiotherapy 
modalities, including hot/cold treatments, electrical stimulation, and hydrotherapy, are 
commonly used in RA treatment. While research does not suggest physiotherapy to have 
a direct effect on the clinical diagnosis, the objectives of this modality include disability 
prevention, increasing functional capability, pain relief, and patient education (Kavuncu 
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& Evcik, 2004). Each of these objectives plays a critical role in improving patient 
outcomes. While there is limited research on the overall effects of physiotherapy for RA 
patients, its ability to improve patient well-being should be fully considered for future 
research. 
 
Psychosocial Interventions and Significance 
 Depression associated directly with RA is not well recognized, nor is it routinely 
treated. Studies show that anywhere from 13-42% of RA patients suffer from major 
depressive disorder (Margaretten et al., 2011). The combination of socioeconomic, 
genetic, and RA disease factors influence the prevalence of depressive disorders amongst 
the RA patient population. Specifically, long-term disability, limited function, and 
systemic inflammation are all associated with the development of depression 
(Margaretten et al., 2011). Moreover, ‘uncontrolled flares’ tend to exacerbate persistent 
RA symptoms and can result in complete cognitive shutdowns and total social 
withdrawals. A study in 2011 explored the attitudes of 67 RA patients concerning their 
perspectives on the psychological and psychosocial impacts of symptomatic flare-ups. A 
few patients in this study reported having “ear-shattering pain” even when no noticeable 
swelling occurred (Hewlett et al., 2011, p. 71). Others described their limited function to 
be unbearable, with one patient stating, “I can’t function like this. I’m hurting, I want to 
kill myself” (Hewlett et al., 2011, p. 72). These statements reveal the intense and 
devastating experiences of RA patients who are forced to endure the effects of 
‘uncontrolled flares.’ These impacts on patient lifestyles, social participation, and overall 
well-being are difficult to comprehend. Psychosocial and psychological interventions 
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should be integral components to the treatment of rheumatoid arthritis. The far-reaching 
systemic effects of this disease require professional involvement. While the emotional 
and mental impacts of RA are often not adequately addressed, they cannot go without 
being recognized. Cognitive approaches for patient therapy have shown to be successful, 
but more research is required to fully undertake and mitigate the depressive effects of 
RA.   
 The efficacy of cognitive-behavioral therapy (CBT) has been studied in various 
settings and trials with patients who have RA. The behavioral component to CBT for RA 
patients involves strategies to help patients find a balance between rest and exercise. 
Cognitive approaches help patients to cope with the stress related to chronic illnesses and 
to develop attitudes of optimism and realism regarding their diagnosis (Koulil et al., 
2018; Sharpe, 2016). Studies show that CBT is considered as one of the most effective 
psychological approaches to managing RA-related pain, while additional strategies such 
as mindfulness-based interventions can benefit RA patients with a history of depressive-
episodes (Sharpe, 2016). In addition to therapies designed to address the psychological 
symptoms associated with RA, a 2010 meta-analysis of randomized controlled trials 
examined self-regulation theory (SRT) and its effect on psychological variables, along 
with its potential ability to increase physical activity in RA patients. Utilizing this active, 
goal-directed approach to managing RA reduced depressive and anxiety symptoms far 
more than in subjects who did not partake in the SRT trials (Knittle et al., 2010). It is 
noteworthy to add that to optimize the efficacy of psychological approaches and to ensure 
successful results, these methods should be utilized early on in the disease process 
(Knittle et al., 2010). 
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CHAPTER NINE 
Rationale 
 
 The findings of the literature review reveal the broad scope of RA as an 
autoimmune disease and thus its complications for treatment. The systemic nature of RA 
makes it a particularly difficult disease to not only diagnose, but to manage over time. 
Despite advancements in the medical treatment of RA, patients still feel as though their 
lives are adversely impacted by the disease and have difficulty rationalizing the risks and 
side effects associated with strong pharmaceutical medications. While many non-
pharmacological treatment options are becoming more widely utilized, their efficacy is 
still not fully understood. Moreover, just because new and emerging treatments are 
insufficiently supported by empirical-based research, it does not necessarily mean that 
they will fail in ameliorating patient symptoms or that they will not become standardized 
in the future. Therefore, a survey was developed to evaluate the experiences and opinions 
of RA patients who had obtained official RA diagnoses. The survey was designed to gain 
additional information regarding patient treatment plans and whether or not patients 
deemed these plans to be effective in managing their RA symptoms or in achieving 
remission. It also gave insight into how this disease has affected patients emotionally, and 
whether they feel their symptoms have been adequately managed. 
 The understanding that many patients will not be diagnosed with RA when they 
first notice symptoms was taken into consideration, along with knowledge of how genetic 
and environmental risk factors may exacerbate symptoms and extra-articular 
manifestations. It was expected that the majority of patients utilize pharmacological 
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treatments and that many may have changed their treatment plans depending on how long 
they have lived with the disease. The hope is for patients and professionals to gain an 
increased awareness of the extensive and systemic nature of this disease beyond 
inflammation of the distal joints. New research regarding treatment options that go 
beyond the restrictions of a medical doctor should continue to be acknowledged and 
researched. A holistic approach is essential to manage and treat such an impactful and 
life-altering disease. 
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CHAPTER TEN 
Methods 
 
Materials  
 The survey was created de novo by the author and approved by the Institutional 
Review Board (IRB) at the University of South Dakota. It was conducted online via 
Google Forms, an online survey collection tool. The IRB approval can be found in 
Appendix B. The survey consisted of 15 multiple choice and free response questions. A 
greater emphasis was placed on free response questions due to the variability in potential 
answers.  
 The survey began by asking generalized questions regarding the individual’s 
gender, age, ethnicity, and age at which they were diagnosed with RA. This was designed 
to obtain an overall understanding of the demographics of the participant and was used to 
compare to the national demographic RA statistics. 
 The survey progressed to gain more specific insight into each participant’s 
experience with RA by asking questions regarding the type of RA they were diagnosed 
with, how their diagnosis made them feel, and what their initial treatment plan entailed. 
The respondents were asked to answer a free response question regarding whether or not 
they had changed treatment plans throughout their disease and to provide an explanation 
as to why they had or had not. 
 The final questions were created to determine what the participants felt had been 
the most effective or least effective regarding their treatment plans. These free response 
questions allowed participants to expand on their answers and provide insight as to how 
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their diagnosis was affecting them currently. The final question asked the respondents to 
disclose whether they felt their symptoms were under control. This was used to gain an 
overall understanding of how participants viewed their disease at this exact point in time, 
regardless of when they were initially diagnosed or how their treatment plans had 
changed. The complete survey is included in Appendix D. 
 
Procedure 
 The survey was distributed to the public via email and social media (i.e. 
Facebook). Included in the invitation was a short description of the survey’s purpose, the 
target group, and a link to the survey on Google Forms. The survey was designed only for 
patients who had been diagnosed with rheumatoid arthritis; it is possible that the survey 
could have been completed by a family member with more advanced computer skills, or 
by an individual who had not received a proper RA diagnosis.  
 Individuals who opened the survey link were directed to Google Forms and 
presented with a complete description of the survey and an informed consent form. All 
participants were informed that their participation was voluntary and to be completed at 
their leisure. Acceptance of the informed consent was implied if the respondent clicked 
“yes” on the opening page to access the survey. No identifying data were collected from 
participants ensuring that all responses were anonymous.  
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CHAPTER ELEVEN  
Patient Survey Results (n = 28) 
 
Figures 2-4: Participant Demographics 
*Question 1 formatted as participant informed consent  
 
 
 
 
 
 
Female
71%
Male
29%
Female
Male
7%
11%
30%
45%
7%
18-22
23-29
30-49
50-64
65+
Figure 2. What is your gender? 
Figure 3. What is your age? 
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Figures and Questions 5-8: Patient Responses to Initial Diagnoses  
 
 
7%
7%
82%
4%
0%
African-American
(non-Hispanic)
Asian/Pacific Islander
White (non-Hispanic)
Latino or Hispanic
Native American or
Aleut
Figure 4. To which racial or ethnic group(s) do you 
most identify?
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Figure 5. How old were you when you were first 
diagnosed with Rheumatoid Arthritis? 
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Figure 6. Responses to “other” option 
 
 “Other” Responses 
 I started noticing differences in my daily fatigue levels but thought I was just overworking myself. Once I 
stepped back from a few responsibilities and the fatigue continued I made an appointment with my doctor 
 I had been exceptionally sore for a long while 
 No, I was just diagnosed recently 
 Shortly after 
 yes, but took 6 months to get into a Rheumatologist 
 Soon after, my knees and lower joints really blew up 
 I wasn't sure what was wrong until the symptoms got really bad 
 I had been having symptoms for a while, but I didn't realize their severity 
  
 I was misdiagnosed 
 
 
 
yes
18%
no
50%
other
32%
yes
no
other
Figure 6. Were you diagnosed immediatley after your 
symotoms first appeared?
25%
36%
14%
25%
Seronegative
Seropositive
Juvenile
Other
Figure 7. What type of Rheumatoid Arthritis were you 
diagnosed with? 
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Figure 7. Responses to “other” option 
 
  
“Other” Responses 
 Unknown 
 I was diagnosed with Lupus 
 unsure 
 Tested positive for RF and ACPA 
 unknown 
 Dr. never specified 
 Ankylosing Spondylitis 
 
 
Question 8 - How did this diagnosis make you feel? 
 
Participant Responses  
 I didn’t really know what to think or how it would affect my life. I had to stop playing many sports which really 
scared me 
 Depressed and anxious 
 sad but relieved 
 Anxious and worried 
 At first fearful, once I met my dr I felt better 
 very sad because I am very active 
 Relieved to have answers! 
 Glad to have a diagnosis for my symptoms. But also afraid of the medications to treat RA. 
 It didn’t affect my feelings until I was about 13 years old because it made me quit all my sports. 
 Scared 
 Ambiguous 
 Worried an unsure of how to best deal with it 
 Very scared, nervous, somewhat relieved to know what was wrong 
 Anxious, upset, wanting more information 
 Unsure, worried 
 Relived I had been fatigued for a very long time prior 
 Concerned 
 I didn’t think it was Lupus. I had to wait a long time to see a Rheumatologist before I got the proper diagnosis 
 I didn’t know RA was an autoimmune disease. I thought I was getting old WAY too fast 
 Relieved 
 Like I was getting older 
 happy to know what it was, scared for what was to come 
 Confused 
 A little anxious, but my doctor helped me to feel better about it 
 Worried, but glad to know I wasn’t going crazy 
 Concerned, but I knew where my fatigue was coming from 
 Annoyed as I have always been very active 
 Confused since my blood tests were not positive 
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Figures and Questions 9-12: Patient Responses to Initial Treatment Plans 
 
 
 
Figure 9. Responses to “other” option 
 
“Other” Responses 
 Methotrexate 
 Cortisone injection under full sedation in both knees and ankles 
 18 Ecotrin aspirin a day 
 
 
Question 10 - Have you changed the course of your treatment during the duration of your 
diagnosis? Why or why not? 
 
“Other” Responses 
 Yes, I originally was only taking Aleve to relieve the pain in my joints. The pain got worse around middle school 
and I was briefly put on steroid medication (which I hated). I have now been taking Meloxicam for years and it 
seems to work great. 
 Somewhat. I added attending a support group several months after being and eventually I’ve added massage and 
acupuncture 
 Not really 
 Started with non-steroidal medicine but I am now taking Humeria one a week 
 We tried multiple medications till we found the biologic that worked. It took two years to gain control with 
biologics and medical cannabis 
 Yes, I have changed drugs several times 
 Yes. Many times. Sometimes due to something not working effectively and other timed due to allergies 
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Figure 9. What did your initial treatment plan entail? 
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 Minimally. I take less methotrexate now since the disease is under control. I also take naproxen for pain control. I 
take less than the recommended dose. 
 Yes because I had knees the size of softballs which made me paralyzed for a short time 
 Yes! So many new meds out today! Thank goodness! 
 Added an additional drug 
 I have added in some dietary changes to try to reduce inflammation. I have added some natural ant inflammatory 
supplements to my routine 
 Yes, I have tried different drugs and exercise during flare ups. My OT has really focused on helping me with 
small daily tasks that I am embarrassed to ask for help with like buttons, cutting food etc 
 yes, as it started to make my joints deteriorate, I had shoulder replacement surgery, have changed my exercise 
habits and have changed medications 
 Yes, 
 Yes 
 No 
 Yes; different therapies, different medication 
 Yes, wasn’t seeing any change from the medications 
 Yes, I began receiving cortisone injections and they have worked quite well 
 Yes, I’ve researched many different anti-inflammatory diets and have yet to find one I like 
 Yes, I’ve changed medications 
 I’ve stuck with the same med for the past few years and they’ve worked great. I still see my OT but not too often 
 yes, I began taking methotrexate in my 20s and it has worked quite well. A few side effects but nothing too harsh 
 Yes, I am deeply involved with the treatment of Rheumatoid Arthritis. I have changed medications many times 
and have developed my won remedies 
 Yes, I was taking methotrexate but found it to negatively affect my lungs 
 yes, I like to keep up-to-date on different DIY treatments along with non-steroidal medications 
 
 
Question 11 – What have you found to be the most effective in regard to your treatment plan? 
 
Participant Responses 
 Medication is best for immediate relief when I have a flareup. Finding support groups and others with my 
diagnosis and talking with therapists to help with depression. Working with professionals to improve my ability 
to do everyday things so that my boyfriend doesn't have to. Adding exercise to my life 
 rest 
 Fish oil supplements 
 remaining active even though some days you don't feel like it 
 My rheumatologist and I keep in touch. I just started on Humira and have found it to be beneficial thus far 
 Biologics 
 My medications 
 The addition of Humira actually put me in remission for two years a few years ago. Unfortunately the disease 
became active again and I am now back on Humira with methotrexate. Also staying physically active is very key 
to keeping the disease from being active 
 Methotrexate 
 Medical cannabis and swimming 
 Combination of all of the previous methods (meds, massage and acupuncture, exercise helps as well but I haven’t 
been good at maintaining just because of time constraints, not arthritis) 
 Lifestyle Changes 
 Naproxen 
 surgery, medication changes, anti-inflammatory supplements and physical therapy after surgery was absolutely 
necessary 
 Taking my medication daily, but also exercise! When I skip a few days of exercise, I am noticeably more stiff 
and sore 
 Humeria or Enbrel 
 Celebrex 
 Therapy 
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 My Rheumatologist has been incredible. He is well aware of the many other manifestations RA can take in the 
body 
 Drugs for pain, exercise for stiffness and better mental health and positivity 
 Heat! 
 THC oil 
 Rituxan was by far the best treatment and the easiest for me to tolerate 
 methotrexate, changing diet to eliminate high inflammatory foods 
 Humira 
 Medication, yoga, and fish oil supplements 
 Communication with my doctor 
 Exercise, change in diet 
 Cortisone injection under full sedation in both knees and ankles 
 18 Ecotrin aspirin a day 
 
 
Question 12 – What have you found to be the least effective or most difficult to attain in regard 
to your treatment plan? 
 
Participant Responses 
 any major dietary changes 
 Pain free days 
 I've heard about changes to diet but I jus haven't been able to force myself to make any concrete changes to my 
diet quite yet 
 None 
 Staying up to date on different at-home remedies. There are too many and they are always changing 
 nothing 
 Dietary changes are hard. Very busy professional. Eat out most nights 
 I am concerned about flareups returning and getting worse 
 Exercise 
 excursive regimens that don't hurt my back 
 Going to therapy - I never have time! 
 exercising regularly without running 
 At home remedies - I can't maintain 
 Consistent morning stretch routine 
 Getting in to see my doctor 
 Use of adaptive equipment. I've had several hand braces over the years and they are uncomfortable and a drag to 
take on and off 
 some of the drugs I took 
 At this point, nothing 
 Non-steroidal medicines 
 Getting off prednisone 
 An exercise plan 
 Changes in diet 
 Changing my diet has been very hard. I a young and it is hard to afford healthy foods and hard to find the time to 
prepare them. I am making small changes and adding new ones that I can manage with my boyfriend. 
 Meloxicam 
 Good diet 
 The side effects of the steriods and getting off them 
 Therapy 
 Dietary changes only because it is hard to change lifelong habits of eating certain foods 
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Figures and Questions 13-16: Patient Responses Regarding Current Symptoms and 
Attitudes  
 
 
 
 
Question 14 – Are there any activities you can no longer pursue due to your Rheumatoid 
Arthritis symptoms? 
 
Participant Responses 
 running 
 I can no longer run because it puts a lot pf pressure on my knees. The same thing goes for really any activities 
that require my body to sort of pound against the ground 
 Not really, except anything related to strength in my arms or putting weight on my wrists when they are bent at 
90 degrees 
 not really, just tire out faster 
 I can do just about anything on a good day but I will be sore from it 
 I was an organist/pianist/accompanist for 25 years in churches. While I may still play the piano for enjoyment, 
the level I was at is now gone 
 No. I stay very physically active, and I think this really helps not only my mental status, but my physical status as 
well 
 Yes, all sports and bike riding 
 Running 
 None 
 Running or walking long distances, typing on a keyboard, holding items for any length time, lifting heavy things 
 Many. I also have to take several days off work whenever I have a flare up. The swelling and pain in my hands is 
the worst because it makes working at a computer almost impossible. My employer is not sympathetic and thinks 
I over state my diagnosis and pain. Anything using my hands has to stop during flareups. Very frustrating 
 No heavy pressure on my shoulders. No weight lifting, limited upper body movement with my arms and 
shoulders 
 Downhill hiking 
 No 
 Running. It takes a long time for my body to warm up to begin exercising 
 It takes me a while to get up and moving in the am 
25%
32%
39%
4%
No pain
Mild pain
Moderate pain
Severe pain
Worse pain
Figure 13. Compared to when you were initially diagnosed, how 
would you rate your pain today?
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 I do not lift as much weight as I use to 
 Sewing 
 My hands don’t grasp my outdoor tools like they used to 
 I’ve been wary to do many activities. It’s been a trial and error process of what causes pain and what does not 
 grasping pencils or moving quickly in the morning 
 I don’t do too many overhead movements when I work out. My shoulders can’t handle much 
 Just the typical “getting older” activities 
 I am not as active as I used to be. I no longer play basketball 
 Hike less 
 
 
 
 
Figure 15. Responses to “other” option 
 
“Other” Responses  
 Yes, but there weren’t many avenues to explore with other people 
 Briefly, after proper diagnosis by my Rheumatologist 
 Has little speech to discuss a determination of this possibility 
 My rheumatologist recommended I join the Arthritis Foundation fb page and I’ve been able to share my 
experiences with others and vice versa 
 
 
 
 
 
 
 
 
 
 
 
Yes
61%
No
25%
Other
14%
Yes
No
Other
Figure 15. Have you ever discussed how your Rheumatoid
Arthritis diagnosis might affect you personally or socially with 
your primary care physician?
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Figure 16. Responses to “other” option 
 
“Other” Responses  
 Will require new shoulders again in ten years. Pain is manageable but the deterioration in the shoulder socket 
continues 
 Occasional flare ups from time to time  
 Yes, the do have flareups every to often but I know how to control them 
 Somewhat. I feel my symptoms could probably be better managed  
 Somewhat. I wish I had more pain free days 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Yes
75%
No
7%
Other
18%
Yes
No
Other
Figure 16. Do you currently feel your Rheumatoid Arthritis 
symptoms are under control? 
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CHAPTER TWELVE 
Discussion 
 
 The results and implications of this survey shed light on many of the challenges 
RA patients face throughout their treatment. From facing unknown or misdiagnoses to 
feeling overwhelming levels of anxiety, fear, and confusion, there is nothing “easy” about 
navigating the world of rheumatoid arthritis and its extra-articular manifestations. In 
total, 28 patients with RA participated in this survey. Many of the free response questions 
required participants to elaborate on particular survey questions, allowing for a detailed 
description of their personal experiences. The results of the survey depict the need for 
additional research and acknowledgment of the extensive effects of this disease. 
Rheumatoid arthritis’ name alone is misleading and confusing to many of those who are 
diagnosed at young ages. The word “arthritis” generally implies aging and the subsequent 
deterioration of the bones and joints. While inflammation, fatigue, and destruction of the 
joints are all major effects of RA, its systemic impact on the body is what makes it 
notably unique and is what differentiates it from other forms of arthritis. The results of 
this survey demonstrate the complexity of this disease and its profound impact on each 
patient as it takes on a chronic state within the body. 
 The respondent demographics aligned with national RA statistics. The majority of 
participants were female and 82% identified as White. However, no participants of this 
study identified as Native American or Aleut (see Figure 2), despite recent research 
suggesting an increase in RA prevalence amongst Native tribes (Ferucci et al., 2005). The 
28 respondents ranged in ages from 18 to over 65 years old, and while varying ages of 
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initial diagnoses of RA were reported, the age ranges of 21-25 and 31-35 were the most 
common (see Figure 5). A possible explanation for this is the fact that 45% of 
participants fell between ages 60-64 and had likely been diagnosed in early to middle-
adulthood (see Figure 3).  
 In regard to the diagnoses of RA, the results of the literature review examined 
how obtaining a formal diagnosis by a rheumatologist or primary physician can be a long 
and frustrating process. For instance, for those patients who do not produce blood 
samples with positive ACPA and RF factors, the diagnosing procedure is based solely 
upon the clinical phenotypic observance of the distal joints. The literature review also 
revealed that many other organ involvements, including that of the heart, lungs, and 
larynx, may be indicative of the presence of RA without any swelling of the distal joints. 
This information suggests that patients may be suffering from the onset of RA symptoms 
without visible inflammation of the joints. Participants in this survey were asked to reveal 
if they had been diagnosed immediately after first noticing their symptoms and the type 
of RA they were diagnosed with. Alarmingly, 50% of participants answered “no” to 
being immediately diagnosed, while 32% answered “other” (see Figure 6). Responses 
within the “other” option included answers ranging from patients being misdiagnosed, 
not realizing the extent of their symptoms, or not being able to make an appointment with 
a rheumatologist for 6 months. Likewise, when asked the type of RA they were 
diagnosed with, 36% of participants reported being diagnosed with seropositive RA, 25% 
seronegative RA, 14% juvenile RA, and 25% reported “other” (see Figure 7). Similar to 
the previous “other” responses, participants who elaborated in this section reported 
answers ranging from not knowing their diagnosis, being misdiagnosed with Lupus, to 
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their doctor never even specifying to them the type of RA their diagnosis entailed (see 
Figure 7). This information is distressing considering that similar to many other chronic 
diseases, treatment intervention of RA is most effective when the disease is detected 
accurately and early in its progression (Heidari, 2011; Mota et al., 2013). In addition, the 
fact that at least three participants did not know what type of RA they were diagnosed 
with is incredibly unsettling. For treatment to be effective, the patient must understand 
the full context of their diagnosis. 
 Similarly, the survey results disclosed pertinent information concerning the 
emotional and psychological toll of RA. When asked how their diagnosis made the 
participants feel, 23 participants reported feelings of worry, concern, anxiety, and 
confusion (see Question 8). While few expressed relief in knowing where their pain, 
fatigue, and symptoms were coming from, the overwhelming majority responded 
otherwise. From the results of the literature review, it was expected for some of the 
participants to not understand their diagnosis. When a young and seemingly healthy 30-
year-old is told they have “arthritis,” it would be surprising if they were not confused. 
This is precisely why professionals should integrate the education of RA and its 
differentiation from other forms of arthritis into their practice. 
 Along with this idea, Figure 15 depicts participant responses to whether or not 
they had ever discussed how their RA diagnosis might affect them personally or socially 
with a physician. 61% of participants responded “yes,” 25% “no,” and 14% responded 
“other.” Among the “other” responses, one participant stated, ‘Yes, but there weren’t 
many avenues to explore with other people’ (see Figure 15). These results signify that 
while it is apt that 61% of patients had discussed with their doctors how their diagnosis 
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might affect them personally or socially, the extent to what actions were taken after this 
discussion is unknown. Because the prevalence of major depressive disorder is so high 
amongst RA patients, this conversation between patient and doctor should be routine. 
This and the availability of more information regarding a patient’s diagnosis should be 
available to mitigate feelings of confusion and worry after the initial diagnosis is made.  
 Figure 9 and Questions 10-12 demonstrate information related to patient 
perspectives regarding their treatment plans and how these plans have changed 
throughout their disease. The results shown in Figure 9 depict that over 25 patients 
reported pharmacotherapy as being included in their initial treatment plans. This survey 
question allowed participants to answer more than one treatment plan; participants may 
likely have chosen a multitude of answers to this particular question. Every treatment 
option available for this question was utilized; however, dietary changes, psychosocial 
interventions, and the use of adaptive equipment were each only reported as being 
included by 3 participants. Four participants answered “other” and each elaborative 
response within the “other” option included the pharmacotherapy use of methotrexate, 
cortisone injection, and aspirin (see Figure 9). While these results confirm medicine to be 
the ‘go-to’ option for initial RA treatment plans amongst the participants, the widespread 
utilization of non-pharmacological options gives insight towards where the future of RA 
treatment may be headed. Even if drug treatment is effective in slowing the progression 
of disease or in alleviating patient symptoms, a patient’s quality of life may still be 
adversely affected. An overwhelming amount of research highlighted in the literature 
review revealed the positive effects of a comprehensive and holistic approach to the 
treatment of RA (Cunningham & Kashikar-Zuck, 2013; Goodacre, 2004; Vlieland, 2007).  
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 Furthermore, when asked how many of the participants had changed the course of 
their treatment plans since their initial diagnoses, 24 reported that they had changed 
medications, while others stated that they had experimented with various self-treatments 
or home remedies (see Question 10). Markedly, participant responses to what they felt 
had been the most effective element of their treatment plans varied immensely. Among 
the vast amount of answers claiming medication to be the most efficacious, methotrexate, 
cortisone injections, and Humira were among the most popular (see Question 11). 
Humira, while not included in the literature review, is a type of medication called a 
biologic. Biologics are special forms of DMARDS that are often prescribed when a 
conventional DMARD is not effective (Biologics, n.d.). Along with this, many responses 
attested to the benefits of being active and consistent with daily lifestyle routines. 
Namely, it is noteworthy to consider the vast number of patients who reported a 
combination of treatments as being the most effective. While not overly popular among 
participant responses, 2 patients reported the use of medical cannabis and THC oil as 
being the most effective treatment modality (see Question 11). Because the benefits of 
medical cannabis and THC oil are not empirically researched to the extent of other 
medications and treatments, it is not well known how their use will impact RA patients 
over time. Nevertheless, the first-ever cannabis-based medical trial for the treatment of 
pain in RA was conducted in 2005; its results are worthy of further research. In a study of 
75 patients, the researchers concluded that cannabis-based medicine produced “a 
significant analgesic effect and disease activity was significantly suppressed” (Blake et 
al., 2005, p. 51). While information and support concerning the use of cannabis in its 
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many forms are new and forthcoming, its efficacy in reducing pain amongst RA patients 
is favorable for larger research.  
 Among participant responses considering what they felt to be least effective in 
treating their symptoms, maintaining exercise regimens, dietary changes, and attending 
therapy were three of the most popular responses. A few respondents reported the use of 
non-steroidal medications to be ineffective, while one respondent stated the side effects 
of steroids as being a hindrance to their treatment plan (see Question 12). Because most 
non-pharmacological approaches entail major changes to the lifestyle, it is 
understandable why so many of the participants feel these are the least effective or most 
difficult to attain. Changing one’s diet or maintaining an exercise regimen can be 
incredibly difficult for healthy adults, let alone for those who are suffering from extreme 
pain, fatigue, and inflammation. While the efficacy of these regimens is well known and 
supported, their implementation may be easier on paper than in one’s actual lifestyle. 
While this may be the case, the effort put in by the participants of this study to try 
different treatment approaches should not be overlooked. 
 To conclude the survey, respondents were asked to compare their pain at the time 
of the survey compared to when they were first diagnosed. The final survey questions 
were designed to ask the participants to reflect on their journey’s with RA and to reveal 
any activities they could no longer pursue due to their symptoms. While three 
respondents revealed that they could still pursue all their activities, the majority of 
responses revealed that the participants could either no longer do certain activities at all, 
or at least not to the extent that they were once able to. Activities like running or hiking 
were popular amongst the responses, likely due to the severe impact of these exercises on 
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the lower joints. Other activities, such as sewing, which require fine motor movements, 
were also common responses (see Question14). Interestingly, compared to when the 
participants were first diagnosed, 25% of participants stated they had “no pain,” 32% had 
“mild pain,” 39% had “moderate pain,” 4% had “severe pain” and 0% reported “worse 
pain” (see Figure 13). Because the majority of patients reported to not be experiencing 
levels of ‘severe pain,’ it can be inferred that their treatment plans are contributing to the 
improvement of their symptoms. Similarly, 75% of patients reported “yes” to their RA 
symptoms currently being under control, while only 7% reported “no” and 18% reported 
“other” (see Figure 16). Among the “other” responses, a few patients felt that their 
symptoms were only “somewhat” controlled, while others seemed to be able to manage 
their pain but were concerned about symptomatic flare-ups.  
 With the vast number of patients reporting that their RA symptoms are under 
control, there is something to be said about the efficacy of their treatment plans. Yet, at 
the same time, this survey highlights the struggles faced by many RA patients when it 
comes to finalizing a treatment plan, maintaining new regimens, and dealing with the 
emotional toll that an RA diagnosis can bring. The need for comprehensive and 
personalized interprofessional teams is integral for the treatment of this complex disease. 
 
Limitations 
 This survey does present a few key limitations. A sample size of only 28 
respondents is not sufficient for this data to be considered significant nor can these 
findings be generalized to the general population. Survey and response bias may be 
present considering the primary researcher and conductor of this survey is also a patient 
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with an RA diagnosis. The survey also failed to depict a correlation between participant 
responses to allow for a more in-depth analysis of the efficacy of each respondent’s 
treatment plans. Along with this, the wording of Question 6 is unclear and does not 
define “immediately” in terms of how long it took for the participants to receive an initial 
diagnosis after first noticing their symptoms (see Figure 6). The variability of answers to 
this question could be misleading. It should also be noted that a few of the research 
findings in the literature review are new and forthcoming, thus their reliability is limited. 
Finally, the validity and reliability of this survey have not been established.  
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CHAPTER THIRTEEN 
Conclusion 
 
 The treatment for rheumatoid arthritis is variable and especially complex due to 
the underlying mechanisms of disease and its manifestations in the non-articular systems 
of the body. While it was once considered to strictly be a disease affecting the synovial 
linings of the distal joints, the overtly systemic impact of RA on all major systems of the 
body is becoming more realized by professionals due to the insights of recent research. 
While the pathogenesis and pathophysiology of the disease are still not well-understood, 
the implications for how genetic and environmental risk factors may exacerbate the 
mechanisms of the disease is central to the current work. 
 Because RA can show symptoms in the body without the clinical phenotypic 
observation of swelling in the distal joints, the results of the literature review reveal the 
urgent need for physicians and rheumatologists to explore non-articular patient symptoms 
with the insight that these symptoms could indicate the early presence of rheumatoid 
arthritis. Observance of the early indicators of disease activity present in the larynx, 
lungs, heart, and vascular systems could be transformative in the detection of RA. With 
knowledge of how the early detection of this disease can impact a patient’s long-term 
prognosis (Hiedari, 2011; Mota et al., 2013), it is inherent for professionals to recognize 
the importance of patient symptoms that go beyond pain, fatigue, and joint inflammation.  
 The optimism demonstrated by the participants of this survey towards the 
exploration of non-pharmacological treatment options for RA indicates the need for 
further research regarding the efficacy of these treatment options. While the medical 
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treatment of RA will surely continue to improve with time, it is in the best interest of all 
RA patients to understand the full range of available treatment options. Likewise, the 
results of the literature review and patient survey affirm the struggles many RA patients 
experience in treating, managing, understanding, and accepting their disease.  
 The overall findings of this literature review and patient study point towards 
adopting a holistic, multifaceted, and interprofessional approach towards the treatment 
and chronic evaluation of rheumatoid arthritis. As an autoimmune disease with many 
manifestations, RA’s elaborate impact within the body can be life-altering and 
devastating. By increasing awareness of the fundamental and unparalleled components of 
this disease, there is hope that future research will be directed towards expanding 
treatment options and improving the experiences and wellbeing of those who are affected 
and impacted by rheumatoid arthritis.  
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Appendix D 
Patient Survey 
 
Rheumatoid Arthritis Journey – A Patient Survey 
Introduction: This research will highlight treatment options and the effectiveness of these 
options in treating Rheumatoid Arthritis. The survey will evaluate the treatment 
experiences of patients who have been diagnosed with Rheumatoid Arthritis and the 
impact of these treatments on their personal medical journeys. To maintain anonymity, 
please refrain from using names or any other identifying information in the free response 
questions. 
1. I have read and understand the previous information regarding my rights as a 
research participant. 
a. Yes 
b. No 
 
Patient Demographics 
2. What is your gender? 
a. Male 
b. Female 
c. Other 
3. What is your age? 
a. 18-22 years old 
b. 23-29 years old 
c. 30-49 years old 
d. 50-64 years old 
e. 65 years and older 
4. To which racial or ethnic group(s) do you most identify? 
a. African-American (non-Hispanic) 
b. Asian/Pacific Islander 
c. White (non-Hispanic) 
d. Latino or Hispanic 
e. Native American or Aleut 
f. Other (please specify) 
 
Patient Responses to Initial Diagnoses 
5. How old were you when you were first diagnosed with Rheumatoid Arthritis? 
a. Entry 
6. Were you diagnosed immediately after your symptoms first appeared? 
a. Yes 
b. No 
c. Other (please explain) 
7. What type of Rheumatoid Arthritis were you diagnosed with? 
a. Seropositive 
b. Seronegative 
c. Juvenile 
d. Other (please explain) 
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8. How did this diagnosis make you feel? 
a. Entry 
 
Patient Responses to Initial Treatment Plans 
9. What did your initial treatment plan entail? Check all that apply 
a. Pharmacotherapy 
b. Holistic remedies 
c. Dietary changes 
d. Altered exercise regimes 
e. Psychosocial interventions 
f. Occupational or physical therapy 
g. Adaptive equipment 
h. Other (please explain) 
10. Have you changed the course of your treatment during the duration of your 
diagnosis? Why or why not? 
a. Entry 
11. What have you found to be the most effective in regard to your treatment plan? 
a. Entry 
12. What have you found to be the least effective or most difficult to attain in regard 
to your treatment plan? 
a. Entry 
 
Patient Responses Regarding Current Symptoms and Attitudes 
13. What have you found to be the least effective or most difficult to attain in regard 
to your treatment plan? 
a. No pain 
b. Mild pain 
c. Moderate pain 
d. Severe pain 
e. Worse pain 
14. Are there any activities you can no longer pursue due to you Rheumatoid Arthritis 
symptoms? 
a. Entry 
15. Have you ever discussed how your Rheumatoid Arthritis diagnosis might affect 
you personally or socially with your primary care physician? 
a. Yes 
b. No 
c. Other (please explain) 
16. Do you currently feel your Rheumatoid Arthritis symptoms are under control? 
a. Yes 
b. No 
c. Other (please explain) 
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